Questions become scenes
Within the divinatory frame, an ordinary dream image is salient because it is read in relation to a prior question about illness, loss, distance or futurity.
Asteraceae · Asterales · Neurolaeneae
Calea zacatechichi
accepted: Calea ternifolia · zacatechichi · bitter grass · dream herb · Mexican calea
Accepted name
Calea ternifolia Kunth · 1818 · Ethnographic record
Oaxaca Chontal · 1960s onward
Botany
| Accepted name | Calea ternifolia Kunth. The name was published in Humboldt, Bonpland and Kunth’s Nova Genera et Species Plantarum in 1818. Calea zacatechichi Schltdl., published in 1835 and retained throughout most psychoactive-plant literature, is treated by Plants of the World Online as a heterotypic synonym (Kunth, 1818; POWO, 2026a, 2026b). |
| Principal synonyms | Calea zacatechichi Schltdl.; C. hypoleuca B.L.Rob. & Greenm.; C. acuminata Standl. & L.O.Williams; C. rugosa (DC.) Hemsl.; C. salmeifolia (DC.) Hemsl.; Alloispermum liebmannii (Sch.Bip. ex Klatt) H.Rob. The unusually broad synonymy reflects variable leaf indumentum and morphology across a wide Mesoamerican range (Wussow et al., 1985; POWO, 2026a). |
| Family | Asteraceae (Compositae), the daisy family; subfamily Asteroideae; tribe Neurolaeneae; subtribe Neurolaeninae. |
| Order | Asterales. |
| Geographic range | Native from Mexico to Colombia, recorded in Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua and multiple Mexican floristic regions. It grows principally in seasonally dry tropical vegetation, scrub, open woodland, roadsides, disturbed slopes and secondary growth, though local populations also occur in moister sites (POWO, 2026a). |
| Local names | Zacatechichi or zacate chichic—from Nahuatl zacatl, grass, and chichic, bitter—alongside zacate amargo, pasto amargo, prodigiosa and Mexican calea. Zoque-Popoluca tam huñi and Mixe poop taam ujts are recorded in medicinal contexts. The form thle-pela-kano/thepelakano, often translated “leaf of God,” circulates as an Oaxaca Chontal name, but orthography and literal gloss should be treated cautiously because most citations return to a small secondary source chain (Díaz, 1979; Leonti et al., 2003; Mata et al., 2022). |
| Growth form | A strongly aromatic and intensely bitter perennial shrub, commonly 0.8–3 m high, with erect to spreading woody stems and dense branching. It can colonise disturbed ground and resprout after cutting. |
| Conservation | No global IUCN Red List assessment was located. POWO records a broad native range, and the species is cultivated internationally, so claims that it is globally endangered are not currently substantiated. Population condition in particular Oaxacan collecting localities, genetic diversity in traded clones and the effects of habitat conversion remain poorly quantified (POWO, 2026a). |
Morphology and reproduction
Stems are cylindrical, striate and pubescent when young, becoming woody with age. Leaves are opposite—occasionally appearing in short crowded groups—petiolate, ovate to elliptic or lanceolate, generally 3–10 cm long, with an acute or acuminate apex and crenate-serrate margins. The upper surface is green and roughened; the lower surface is paler, prominently veined and variably hairy. Secretory and non-glandular trichomes contribute to both taxonomic diagnosis and the characteristic bitter-aromatic profile (Wussow et al., 1985; Raman et al., 2023).
The apparent “flowers” are small composite capitula arranged in terminal or axillary corymbose clusters. Each head bears a narrow involucre of bracts and a small number of white to cream tubular disc florets; showy ray florets are absent. The corolla is five-lobed, the anthers form the syngenesious tube typical of Asteraceae, and the style divides into two branches. Fruits are slender, ribbed cypselae conventionally called achenes, crowned by a pappus of short scales that assists dispersal. Seed is produced, while cultivated material is commonly maintained clonally by cuttings (Mata et al., 2022).
Identity boundaries
Current taxonomy
The accepted species is Calea ternifolia; C. zacatechichi is a synonym, not a second dream-herb species. Retaining the latter in the page title preserves ethnographic and pharmacological discoverability while displaying the accepted name explicitly.
“Aztec dream herb”
The commercial phrase projects a documented twentieth-century Oaxaca Chontal report backward into an unspecified Aztec past. Nahuatl etymology demonstrates circulation of a bitter-grass name, not the identity, preparation or ritual use of a particular pre-Hispanic taxon.
Common adulterant
Chromolaena odorata, sold as “non-bitter calea,” is morphologically and chemically distinct and may contain pyrrolizidine alkaloids. Microscopy, HPTLC and UHPLC-MS differentiate it from authentic C. ternifolia (Raman et al., 2023).
Chemotypes
At least dozens of sesquiterpene lactones and other metabolites occur across material assigned to the species. The effects of geography, variety, season and cultivation on an oneirogenic chemical profile have not been mapped adequately.
Chemistry
Calea ternifolia is not known to contain a classical serotonergic psychedelic such as mescaline, psilocin or DMT. Its principal specialised metabolites are germacranolide and related sesquiterpene lactones—caleins, caleicines, zexbrevin and multiple analogues—together with chromenes, coumarins, acetylenes, flavonoids, flavonoid glycosides, phenylpropanoids and quinic-acid derivatives. More than sixty named constituents had been collated by 2021; a 2023 authentication study annotated over thirty compounds and detected nineteen sesquiterpene lactones in verified samples. No compound or fixed combination has yet been demonstrated to be the human oneirogenic principle (Herz and Kumar, 1980; Mata et al., 2022; Raman et al., 2023).
GERM
LACTONE
LACTONE
Calein A
Germacranolide sesquiterpene lactone
A major bitter constituent reported from infusions and organic extracts
Biological activity demonstrated preclinically · oneirogenic role unproven
GERM
LACTONE
LACTONE
Calein C
Germacranolide sesquiterpene lactone
One of several caleins with variable acyl substitution
Metabolic and antiparasitic studies · CNS mechanism unresolved
Acacetin
C₁₆H₁₂O₅
5,7-dihydroxy-4′-methoxyflavone
Flavone detected in aqueous extracts · broad preclinical pharmacology
Chlorogenic acid
C₁₆H₁₈O₉
5-O-caffeoylquinic acid
Phenolic acid in infusions · not specific to Calea
The unlocated oneirogenic principle
Mayagoitia, Díaz and Contreras found methanolic and aqueous-related fractions more behaviourally active than a non-polar hexane fraction, directing attention toward relatively polar constituents, but their experiment did not isolate an active molecule. Later aqueous-extract profiling identified chlorogenic acid, rutin-related flavonoids, acacetin-related compounds, calealactone C and calein A. Rodent results differ with extract, dose and behavioural paradigm: one study found little central activity apart from increased immobility and peripheral antinociception; another reported anxiolytic- and antidepressant-like behaviour, increased slow-wave sleep at a high dose and greater hippocampal gamma power during REM sleep (Mayagoitia et al., 1986; Sałaga et al., 2016; Martínez-Mota et al., 2021).
Claims that “caleicine is a prodrug of eugenol” or that a single constituent acts as a proven GABAergic dream molecule are repeated online but are not established by the primary human literature. The known lactones are reactive bitter plant-defence compounds with multiple biological targets; the plant’s effects may arise from a chemical ensemble, altered sleep continuity, sensory expectancy and the interpretive practice surrounding dreams rather than one receptor-selective hallucinogen.
Pharmacological evidence map
Human sleep signal
A small double-blind study found increased reaction time and time-estimation, more light sleep and spontaneous awakenings, and more dream or hypnagogic-image reports than diazepam and, for the methanol extract, placebo. Sample size and replication are limited (Mayagoitia et al., 1986).
REM physiology
In rats, an aqueous extract increased slow-wave-sleep episodes at 100 mg/kg and hippocampal 31–50 Hz power during REM. This is a rodent electrophysiological correlate, not evidence that a particular compound induces lucid dreaming in humans (Martínez-Mota et al., 2021).
Peripheral medicine
Animal and in-vitro studies report antidiarrhoeal, antinociceptive, anti-inflammatory, antihyperglycaemic, antiplasmodial and antileishmanial activities. These findings illuminate bitter-medicine uses but do not establish clinical efficacy (Venegas-Flores et al., 2002; Sałaga et al., 2015; Escandón-Rivera et al., 2017).
Toxicology
Human proximal-tubule cells showed extract-associated cytotoxicity, ROS generation and mitochondrial effects; other experimental work has produced mixed liver, kidney and erythrocyte findings. A 2025 neuronal-cell study reported cholinergic and dopaminergic enzyme inhibition together with neuroglial membrane toxicity at experimental concentrations (Mossoba et al., 2016; González-Yáñez et al., 2019; Garcia et al., 2025).
Tradition, ritual & cultural use
| Oldest evidenced use | No securely identified archaeological residue, iconography or pre-Columbian written reference demonstrates the species’ oneirogenic use. The earliest botanical description is Kunth’s 1818 C. ternifolia; Schlechtendal named C. zacatechichi in 1835. The first specific published notice of “psychic properties” is Thomas MacDougall’s 1968 account after fieldwork among the Chontal of Oaxaca, followed by Díaz’s 1979 taxonomic-ethnopharmacological synthesis (MacDougall, 1968; Díaz, 1979; Mata et al., 2022). |
| Primary people | The oneirogenic record concerns Chontal communities of Oaxaca—speakers of Tequistlatecan languages in the Sierra and coastal Isthmus—not the Maya-language Yokot’an/Chontal people of Tabasco. “Chontal” is a Nahuatl-derived exonym applied historically to unrelated peoples; the phrase “Chontal Maya of Oaxaca” is therefore erroneous (Díaz, 1979; Campbell, 1997). |
| Other medicinal traditions | Mixe and Zoque-Popoluca pharmacopoeias record cognate bitter remedies for stomachache, diarrhoea, cough, asthma and fever. Wider Mexican uses include periodic fever, dysentery, poor appetite, “bile,” diabetes, skin complaints and gynaecological or respiratory conditions. These records do not all entail dream divination (Leonti et al., 2003; Mata et al., 2022). |
| Traditional preparation | Published Chontal accounts describe dried leaves taken as a bitter infusion, smoked in a leaf cigarette, or used in both forms before sleep; leaves are also reported near or beneath the pillow. The diagnostic aim is to frame a question and attend to the dream, rather than to sustain a prolonged waking intoxication (MacDougall, 1968; Díaz, 1979; Mayagoitia et al., 1986). |
| Ritual scale | Small, nocturnal and diagnostic. Sources refer to healers or knowledgeable persons as well as individual sleepers, but do not document a centralised priesthood, pilgrimage, temple cult or standard public liturgy. |
Oneiromancy as diagnosis
The ethnographic proposition is concise: when ordinary perception cannot establish why someone is ill, where a person or object has gone, or what an uncertain future contains, the question is transferred to dream. The plant is said to “clarify the senses”; somnolence, calm and awareness of heartbeat mark the approach to sleep; an image, encounter or event in the ensuing dream can then be interpreted as information. This is oneiromancy in the strict sense—divination by dreaming—not necessarily “lucid dreaming” as defined in contemporary sleep science, where the dreamer recognises the dream while it is occurring (MacDougall, 1968; Díaz, 1979; Mayagoitia et al., 1986).
The medicinal and divinatory domains are not separable in a modern clinical manner. A dream may disclose the social, spiritual or situational cause of illness, while the same bitter plant also addresses fever, appetite and gastrointestinal disturbance. Yet the evidence does not warrant turning every use of Calea into shamanism. Mixe and Zoque-Popoluca stomach and respiratory remedies, for example, are important ethnomedical records without documented oneiromantic content (Leonti et al., 2003).
People, language and the literature’s distortions
Role in healing specialism
Díaz’s account places Calea among plants used by Chontal curers, and later summaries commonly call the operator a shaman. The more precise analytical category is a dream-diagnostic specialist or curandero: someone who integrates botanical medicine, questioning, sleep and interpretation. The plant does not by itself define a pan-Mesoamerican “Calea shamanism,” and the extant literature is too thin to reconstruct apprenticeship, gender, payment, song, altar architecture or a stable sequence of ritual offices.
Cosmology & key terms
The dream as an epistemic place
The documented cosmological fact is functional rather than mythographic: dreaming can yield information unavailable to waking inquiry. Illness and absence are not merely objects to be represented by a dream; they can be approached through it. The plant’s role is therefore mediatory. It changes the conditions of sleeping, recall and attention so that a nocturnal image may be received as an answer. This configuration belongs to a much wider human history of incubation—sleep undertaken in order to receive diagnosis or counsel—but the Chontal practice should not be reduced to a generic global archetype (Díaz, 1979; Tedlock, 1992).
Names, gods and unsupported myth
The name zacatechichi carries a sensory taxonomy: bitter grass. The reported Chontal expression thle-pela-kano is repeatedly glossed “leaf of God,” suggesting divine or more-than-human authorization, yet published orthographies vary and the primary linguistic documentation is rarely supplied. No stable corpus of named Calea deities, origin narratives or ritual chants appears in the available ethnography. Claims that the plant carried Aztec sorcerers into Tlalocan, that it was a pre-Columbian sacrament, or that it belonged to a homogeneous “Chontal Maya” religion are modern abductive elaborations, not evidenced history.
Material culture of a quiet rite
Comparative oneirogenic field
Calea is now grouped with Silene undulata, Entada rheedei, Artemisia vulgaris, Heimia salicifolia and iboga under the modern category “dream herbs” or oneirogens. That category is useful phenomenologically but can erase radically different institutions: Xhosa initiation, African healing, European herb lore, Oaxacan diagnosis and online lucid-dream practice are not variants of one ritual complex. Calea is distinctive because a specific dream-divination report was followed by a rare—though very small—human sleep experiment.
Visionary phenomenology
Primary temporal fieldsleep onset → nap/nightEffects are sought around recumbency rather than as a sustained waking visionary session.
Waking intensitysubtle–moderateBitterness, calm, heaviness, somnolence and bodily pulse awareness predominate in reports.
Visionary locushypnagogia + dreamBrief imagery near sleep and remembered dreams, not reliably open-eyed waking hallucination.
Experimental signalmore light sleepSuperficial stages and spontaneous awakenings increased in a small 1986 study.
Dream qualitymore reports, shorter narrativesThe methanolic extract produced more recalled dream episodes without longer written content.
Luciditynot establishedDream recall or vivid hypnagogia is not equivalent to metacognitive awareness within the dream.
The experiential arc
Bitterness
Infusion produces an unusually persistent bitter taste; smoke adds a dry aromatic harshness. This first event often dominates contemporary reports and is culturally encoded in the plant’s Nahuatl name.
Quieting
Accounts describe tranquillity, lassitude and drowsiness, sometimes with amplified awareness of pulse or heartbeat. Strong euphoria is not a stable feature.
Hypnagogic image
Short visual scenes, faces, landscapes or auditory fragments may arise while awareness of the room is fading. Frequent light-sleep transitions can multiply opportunities to notice them.
Dream episode
Reports emphasise vividness, density, strangeness or apparent meaningfulness. In Chontal divination, relevance to the question matters more than spectacular imagery.
Recall and reading
Spontaneous awakening may make a just-finished image easier to retain. Interpretation—diagnostic, divinatory or psychological—completes the experience.
What the human experiment actually found
Mayagoitia and colleagues compared low doses of organic extracts with placebo and diazepam in healthy volunteers. Reaction time and subjective time-lapse estimation increased. In controlled naps the extracts shifted sleep toward superficial stages and increased spontaneous awakenings; subjective dream reports were greater than after diazepam and, with the methanolic extract, significantly greater than placebo. Reports were more numerous but shorter, without clear increases in nightmare or emotional content. The authors interpreted this as enhanced hypnagogic imagery in light sleep, not as proof of prophetic dreams or stable lucid-dream induction (Mayagoitia et al., 1986).
> increased the superficial stages of sleep and the number of spontaneous awakenings — — Mayagoitia, Díaz and Contreras (1986, p. 229)
Salient experiential motifs
Vividness without grandeur
Contemporary anecdotes often describe sharper colour, lifelike people or rapid narrative shifts, but many users report little beyond sleep disruption or no discernible effect.
Fragmentation aids memory
More awakenings can increase the chance of remembering a dream immediately after it ends. The resulting experience may feel “more dreamful” even without increased total REM time.
Interpretation is causal
Preparation, expectancy, the posed question and post-waking narration organise which fragments count as meaningful; phenomenology is co-produced by plant, sleep architecture and practice.
Duration and intensity: evidence limits
A precise pharmacokinetic onset or elimination half-life has not been established in humans. Oral and smoked traditions place subjective changes within the approach to sleep, while the relevant observational window is the ensuing nap or night. “Duration” therefore means the period in which sleep transitions, awakenings and recalled dreams are altered, not a well-demarcated intoxication curve. Extract concentration, plant identity, sleep debt, expectancy and recall practice probably account for much inter-individual variation.
Contemporary status
From diagnostic plant to lucid-dream technology
Since the 1990s, entheogenic seed catalogues, lucid-dream manuals and online forums have relocated Calea into a transnational oneironautic repertoire. Whole leaf is sold beside tinctures, resins, “10×” or “20×” extracts, smoking mixtures and combinations with mugwort, blue lotus, passionflower, galantamine or melatonin. The desired outcome also changes: Oaxacan diagnostic dreaming becomes dream vividness, recall, lucidity, astral travel, creativity or quantified sleep optimisation. These are contemporary cultural transformations, not simple survivals of one Chontal rite.
Economy, authenticity and conservation
No reliable global production or export series exists for Calea. Commerce is dispersed across Mexican and Central American herb supply, specialist nurseries, supplement firms and online marketplaces. Cultivated clones travel readily, while powders and extracts erase diagnostic morphology. Raman and colleagues demonstrated that commercial “non-bitter calea” may be Chromolaena odorata, a chemically distinct species with pyrrolizidine-alkaloid concerns; authentic C. ternifolia contained a much richer sesquiterpene-lactone fingerprint (Raman et al., 2023). The most immediate biocultural threat is therefore not proven global botanical scarcity but loss of species identity and of the specific people, language and diagnostic relations from which “dream herb” acquired value.
Legal position · checked 7 August 2026
| International | Calea ternifolia, C. zacatechichi and its known constituents are not scheduled by the 1961, 1971 or 1988 United Nations drug-control conventions. |
| United States | No federal Controlled Substances Act scheduling was located. Louisiana Revised Statutes §40:989 lists Calea zacatechichi among “hallucinogenic plants” whose production, manufacture, distribution or possession is prohibited when intended for human consumption; ornamental possession is treated differently (Louisiana Legislature, 2026). |
| Poland | Added in 2009 to Poland’s controlled plant list under amendments to the Act on Counteracting Drug Addiction. Polish psychiatric literature records it among the psychoactive species prohibited by that amendment (Simonienko et al., 2013). |
| United Kingdom | Not named as a controlled drug under the Misuse of Drugs Act schedules. Supply of a product capable of producing a psychoactive effect may fall within the broad Psychoactive Substances Act 2016; status depends on statutory definitions and evidence, not on a specific Calea listing (UK Government, 2016). |
| Elsewhere | Often unscheduled as a named species, though medicine, novel-psychoactive-substance, smoking-product, food and import law may govern particular preparations. “Legal” is not a stable global attribute of the plant. |
Patents and enclosure
Patent documents illustrate the conversion of an ethnobotanical reputation into formulation claims. US8092840B2 claims a dietary supplement for sleep and lucid dreaming whose principal ingredients include Calea powder, 5-HTP and vinpocetine with melatonin and other herbs. US20040266659A1 cites Calea as prior art while claiming acetylcholinesterase-inhibitor approaches to dream recall and lucidity. Neither patent establishes ownership of the species or of Chontal knowledge; they claim specific modern formulations or methods. Their significance is anthropological as much as technical: a diagnostic plant becomes an ingredient in a proprietary sleep stack (US20040266659A1, 2004; US8092840B2, 2012).
Research frontier
2023 authentication
Macro-microscopy, HPTLC and UHPLC-UV-MS now provide orthogonal methods for distinguishing C. ternifolia from Chromolaena odorata; this is essential for every future pharmacological or clinical claim (Raman et al., 2023).
2024 dream review
A review of pharmacological lucid-dream induction concluded that cholinergic candidates such as galantamine have the strongest evidence; Calea remains an intriguing but weakly replicated botanical case (Oldoni et al., 2024).
2025 neurotoxicity
Garcia and colleagues chemically characterised an extract and reported cholinesterase and monoamine-oxidase effects alongside concentration-dependent neuronal and glial toxicity in vitro. It does not determine traditional human risk, but complicates simple “natural sleep aid” narratives (Garcia et al., 2025).
Needed study
A voucher-authenticated, preregistered human polysomnography trial should separate REM time, N1/N2 fragmentation, awakenings, dream recall, vividness and verified lucidity while chemically characterising the administered material.
Bibliography
Harvard style (Cite Them Right) · DOI and stable-record links ·
35 sources
Art, music & material culture
01 · 3 sources
GreenZeb (2013) ‘Calea ternifolia’, photograph via Wikimedia Commons. CC BY-SA 3.0.
Hofford, C. (2018) ‘Calea ternifolia (syn. Calea zacatechichi) Dream Herb’, photograph at the United States Botanic Garden, via Wikimedia Commons. CC BY-SA 4.0.
Rizzone, M. (2008) ‘Calea flowering’, photograph via Wikimedia Commons. CC BY-SA 4.0.
Botany & taxonomy
02 · 7 sources
Kunth, C.S. (1818) ‘Calea ternifolia’, in Humboldt, F.W.H.A., Bonpland, A.J.A. and Kunth, C.S., Nova Genera et Species Plantarum, 4, p. 231. Paris.
Mata, R., Contreras-Rosales, A.J., Gutiérrez-González, J.A., Villaseñor, J.L. and Pérez-Vásquez, A. (2022) ‘Calea ternifolia Kunth, the Mexican “dream herb”, a concise review’, Botany, 100(2), pp. 261–274. Available at: https://doi.org/10.1139/cjb-2021-0063.
Plants of the World Online (POWO) (2026a) ‘Calea ternifolia Kunth’. Royal Botanic Gardens, Kew. Available at: powo.science.kew.org (Accessed: 7 August 2026).
Plants of the World Online (POWO) (2026b) ‘Calea zacatechichi Schltdl.’ Royal Botanic Gardens, Kew. Available at: powo.science.kew.org (Accessed: 7 August 2026).
Raman, V., Wang, Y.-H., Saroja, S.G. et al. (2023) ‘Characterization of Calea ternifolia and its adulterant Chromolaena odorata using macro-microscopy, HPTLC and UHPLC-UV–MS’, Revista Brasileira de Farmacognosia, 33, pp. 790–801. Available at: https://doi.org/10.1007/s43450-023-00411-9.
Schlechtendal, D.F.L. von (1835) ‘Calea zacatechichi’, Linnaea, 9, pp. 589–590.
Wussow, J.R., Urbatsch, L.E. and Sullivan, G.A. (1985) ‘Calea (Asteraceae) in Mexico, Central America, and Jamaica’, Systematic Botany, 10(2), pp. 241–267. Available at: JSTOR 2418590.
Chemistry & pharmacology
03 · 11 sources
Bork, P.M., Schmitz, M.L., Kuhnt, M., Escher, C. and Heinrich, M. (1997) ‘Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-κB’, FEBS Letters, 402(1), pp. 85–90. Available at: https://doi.org/10.1016/S0014-5793(96)01502-5.
Escandón-Rivera, S., Pérez-Vásquez, A., Navarrete, A., Hernández, M., Linares, E., Bye, R. and Mata, R. (2017) ‘Anti-hyperglycemic activity of major compounds from Calea ternifolia’, Molecules, 22(2), 289. Available at: https://doi.org/10.3390/molecules22020289.
Garcia, M.R., Ferreres, F., Mineiro, T. et al. (2025) ‘Mexican calea (Calea zacatechichi Schltdl.) interferes with cholinergic and dopaminergic pathways and causes neuroglial toxicity’, Journal of Ethnopharmacology, 337(3), 118915. Available at: https://doi.org/10.1016/j.jep.2024.118915.
González-Yáñez, L., Rivas-Morales, C., Oranday-Cárdenas, M.A. et al. (2019) ‘Safety of aqueous extract of Calea ternifolia used in Mexican traditional medicine’, Evidence-Based Complementary and Alternative Medicine, 2019, 7478152. Available at: https://doi.org/10.1155/2019/7478152.
Herz, W. and Kumar, N. (1980) ‘Sesquiterpene lactones of Calea zacatechichi and C. urticifolia’, Phytochemistry, 19(4), pp. 593–597. Available at: https://doi.org/10.1016/0031-9422(80)87022-1.
Lee, I.-Y., Fronczek, F.R., Malcolm, A., Fischer, N.H. and Urbatsch, L.E. (1982b) ‘New germacranolides from Calea ternifolia and the molecular structure of 9α-hydroxy-11,13-dihydro-11α,13-epoxyatripliciolide-8β-O-(2-methylacrylate)’, Journal of Natural Products, 45(3), pp. 311–316. Available at: https://doi.org/10.1021/np50021a012.
Lee, I.-Y., Olivier, E.J., Urbatsch, L.E. and Fischer, N.H. (1982a) ‘Two sesquiterpene lactones of Calea ternifolia var. calyculata’, Phytochemistry, 21(9), pp. 2313–2316. Available at: https://doi.org/10.1016/0031-9422(82)85197-2.
Mossoba, M.E., Flynn, T.J., Vohra, S., Wiesenfeld, P. and Sprando, R.L. (2016) ‘Evaluation of “dream herb,” Calea zacatechichi, for nephrotoxicity using human kidney proximal tubule cells’, Journal of Toxicology, 2016, 9794570. Available at: https://doi.org/10.1155/2016/9794570.
Sałaga, M., Kowalczuk, A., Zielinska, M. et al. (2015) ‘Calea zacatechichi dichloromethane extract exhibits antidiarrheal and antinociceptive effects in mouse models mimicking irritable bowel syndrome’, Naunyn-Schmiedeberg’s Archives of Pharmacology, 388, pp. 1069–1077. Available at: https://doi.org/10.1007/s00210-015-1142-1.
Venegas-Flores, H., Segura-Cobos, D. and Vázquez-Cruz, B. (2002) ‘Antiinflammatory activity of the aqueous extract of Calea zacatechichi’, Proceedings of the Western Pharmacology Society, 45, pp. 110–111.
Wu, H., Fronczek, F.R., Burandt, C.L. and Zjawiony, J.K. (2011) ‘Antileishmanial germacranolides from Calea zacatechichi’, Planta Medica, 77(7), pp. 749–753. Available at: https://doi.org/10.1055/s-0030-1250584.
Ethnography, ritual & cosmology
04 · 5 sources
Campbell, L. (1997) American Indian Languages: The Historical Linguistics of Native America. Oxford: Oxford University Press.
Díaz, J.L. (1979) ‘Ethnopharmacology and taxonomy of Mexican psychodysleptic plants’, Journal of Psychedelic Drugs, 11(1–2), pp. 71–101. Available at: https://doi.org/10.1080/02791072.1979.10472094.
Leonti, M., Sticher, O. and Heinrich, M. (2003) ‘Antiquity of medicinal plant usage in two Macro-Mayan ethnic groups (Mexico)’, Journal of Ethnopharmacology, 88(2–3), pp. 119–124. Available at: https://doi.org/10.1016/S0378-8741(03)00188-0.
MacDougall, T. (1968) ‘Calea zacatechichi: a Compositae with psychic properties?’, Garden Journal, 18, p. 105.
Tedlock, B. (1992) Time and the Highland Maya, revised edn. Albuquerque: University of New Mexico Press.
Law, policy & patents
05 · 5 sources
Louisiana Legislature (2026) Louisiana Revised Statutes §40:989: Unlawful production, manufacture, distribution, or possession of hallucinogenic plants. Available at: legis.la.gov (Accessed: 7 August 2026).
Simonienko, K., Waszkiewicz, N. and Szulc, A. (2013) ‘Psychoactive plant species—actual list of plants prohibited in Poland’, Psychiatria Polska, 47(3), pp. 499–508.
UK Government (2016) Psychoactive Substances Act 2016. London: The Stationery Office. Available at: legislation.gov.uk.
US20040266659A1 (2004) ‘Substances that enhance recall and lucidity during dreaming’. United States patent application. Available at: Google Patents.
US8092840B2 (2012) ‘Dietary supplement and a method to enhance sleep and lucid dreaming’. United States patent. Available at: Google Patents.
Visionary phenomenology
06 · 4 sources
Martínez-Mota, L., Cruz-Tavera, A., Machorro-Rojas, N. et al. (2021) ‘Calea zacatechichi Schltdl. (Compositae) produces anxiolytic- and antidepressant-like effects, and increases the hippocampal activity during REM sleep in rodents’, Journal of Ethnopharmacology, 265, 113316. Available at: https://doi.org/10.1016/j.jep.2020.113316.
Mayagoitia, L., Díaz, J.L. and Contreras, C.M. (1986) ‘Psychopharmacologic analysis of an alleged oneirogenic plant: Calea zacatechichi’, Journal of Ethnopharmacology, 18(3), pp. 229–243. Available at: https://doi.org/10.1016/0378-8741(86)90002-4.
Oldoni, A.A., Carvalho, L.S., Bittencourt, L. et al. (2024) ‘Neuropsychopharmacological induction of (lucid) dreams: a narrative review’, Brain Sciences, 14(5), 426. Available at: https://doi.org/10.3390/brainsci14050426.
Sałaga, M., Fichna, J., Socała, K. et al. (2016) ‘Neuropharmacological characterization of the oneirogenic Mexican plant Calea zacatechichi aqueous extract in mice’, Metabolic Brain Disease, 31, pp. 631–641. Available at: https://doi.org/10.1007/s11011-016-9794-1.
Cross-correlations
| Salvia divinorum | Species monograph: another Oaxacan divinatory medicine, Mazatec rather than Chontal, whose waking visionary phenomenology and κ-opioid chemistry differ sharply. REGIONAL DIVINATORY COMPARATOR |
| Ipomoea corymbosa | Species monograph: a Mesoamerican divinatory seed medicine with colonial documentation and ergoline chemistry. HISTORICAL-EVIDENCE COMPARATOR |
| Heimia salicifolia | Species monograph: Mexican and Central American medicine later enrolled in global “dream herb” discourse, with a different and contested psychoactive record. ONEIROGENIC COMPARATOR |
| Nicotiana rustica | Species monograph: smoke as medicine and divinatory medium across the Americas; nicotinic pharmacology and public ritual scale differ from Calea. SMOKE-MEDICINE COMPARATOR |
| Tabernanthe iboga | Species monograph: a powerful waking oneirogenic and initiatory medicine whose visionary duration and institutions exceed the quiet sleep-threshold practice documented for Calea. ONEIRIC CONTRAST |
| Mazatec Divinatory Medicine Complex | Complex page: nearby but ethnolinguistically distinct mushroom, Salvia, tobacco and seed practices. Calea should not be assigned to the complex without direct Mazatec evidence. REGIONAL BOUNDARY |